Humoral immune response to adenovirus induce tolerogenic bystander dendritic cells that promote generation of regulatory T cells

PLoS Pathog. 2018 Aug 20;14(8):e1007127. doi: 10.1371/journal.ppat.1007127. eCollection 2018 Aug.

Abstract

Following repeated encounters with adenoviruses most of us develop robust humoral and cellular immune responses that are thought to act together to combat ongoing and subsequent infections. Yet in spite of robust immune responses, adenoviruses establish subclinical persistent infections that can last for decades. While adenovirus persistence pose minimal risk in B-cell compromised individuals, if T-cell immunity is severely compromised reactivation of latent adenoviruses can be life threatening. This dichotomy led us to ask how anti-adenovirus antibodies influence adenovirus T-cell immunity. Using primary human blood cells, transcriptome and secretome profiling, and pharmacological, biochemical, genetic, molecular, and cell biological approaches, we initially found that healthy adults harbor adenovirus-specific regulatory T cells (Tregs). As peripherally induced Tregs are generated by tolerogenic dendritic cells (DCs), we then addressed how tolerogenic DCs could be created. Here, we demonstrate that DCs that take up immunoglobulin-complexed (IC)-adenoviruses create an environment that causes bystander DCs to become tolerogenic. These adenovirus antigen loaded tolerogenic DCs can drive naïve T cells to mature into adenovirus-specific Tregs. Our study reveals a mechanism by which an antiviral humoral responses could, counterintuitively, favor virus persistence.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenoviridae / immunology
  • Adenoviridae Infections / immunology*
  • Cell Differentiation / immunology
  • Dendritic Cells / immunology*
  • Humans
  • Immune Evasion / immunology*
  • Immunity, Humoral / immunology*
  • T-Lymphocytes, Regulatory / immunology*

Grants and funding

This study was funded through the Marie Sklodowska-Curie actions initial training network (FP7 ITN; ADVance #290002) (EJK), the Agence Nationale de la Recherche (ANR, DCTaxis) (EJK), Swiss National Science Foundation (#320030_173071) (MP), the Labex EpiGenMed (EJK), an ANR "Investissements d'avenir" program, (ANR-10-LABX-12-01) (EJK), the Université de Montpellier (Soutien a la Recherche) (EJK), Vietnamese Minister of Education (TTPT), the Innovative Medicine Initiative EboVac2 (#115861) (EJK), and L'institut de Génétique Moléculaire de Montpellier (EJK). EJK is an Inserm fellow. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.